Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma

• Conditions: Pheochromocytoma; Paraganglioma
• Interventions: Other: Catecholamines

• Registration Number: NCT05451134
• Lead Sponsor: China National Center for Cardiovascular Diseases

Brief Summary

The investigators will retrospectively analyze the clinical data of consecutive patients with pheochromocytomas and paragangliomas admitted between January 2018 and June 2020. The clinical characteristics of patients with and without dysglycemia will be compared, and whether surgery could improve the patients'dysglycemia will be also investigated.

Detailed Description

This retrospective cohort study will include all consecutive adult patients who underwent surgery for PHEOs and catecholamine-secreting PGLs from January 2018 to June 2020. Patients with recurrent PPGLs, those who required steroids after adrenalectomy, and those with inadequate clinical records were excluded. The patients' electronic medical files were reviewed. Patients with dysglycemia included those with diabetes, or impaired fasting glucose, or impaired glucose tolerance. Clinical history data such as age, sex, body mass index (BMI), the presence of preoperative symptoms, biochemical test results, and tumor characteristics, such as tumor diameters and locations were extracted and analyzed.

Study Timeline

• Status Verified: 2022-06
• Study Start: 2022-06-30
• Study First Submitted: 2022-06-30
• Study First Submitted QC: 2022-07-05
• Last Update Submitted: 2022-07-09
• Study First Posted: 2022-07-11
• Last Update Posted: 2022-07-12
• Primary Completion: 2022-07-20
• Study Completion: 2022-07-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• age ≥18 years old
• patients with surgical pathological diagnosis of pheochromocytomas and paragangliomas(PPGLs)

Exclusion Criteria

• recurrent PPGLs
• patients who required steroids after adrenalectomy
• patients with inadequate clinical records were excluded.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients without dysglycemia	Catecholamines	Patients without dysglycemia in the included subjects with pheochromocytoma and paraganglioma
patients with dysglycemia	Catecholamines	Patients with dysglycemia in the included subjects with pheochromocytoma and paraganglioma

Primary Outcome Measures

Name	Time	Method
Change from baseline OGTT（oral glucose tolerance test）results to 6-12 months after surgery	Baseline, 6-12 months after surgery	OGTT results （including fasting blood glucose in the text, blood glucose results at 2 hours after oral administration of 75g glucose）at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia

Secondary Outcome Measures

Name	Time	Method
random blood glucose results	baseline, 6-12 months after surgery	random blood glucose results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia
HbA1c	baseline, 6-12 months after surgery	HbA1c results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia
fasting blood glucose	baseline, 6-12 months after surgery	fasting blood glucose results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia

Trial Locations

Locations (1)

Xian-Liang Zhou; 🇨🇳 Beijing, Beijing, China